Chronic Kidney Disease in the Elderly

Clinics in Geriatric Medicine

Volumn 29, Issue 3, 2013, Pages 611-624

  Maw, Thin Thin ^a   Fried, Linda ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Chronic kidney disease; Dialysis; Elderly; Geriatric; Renal function

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE;

ACUTE KIDNEY FAILURE; AGED; AGING; ALBUMINURIA; BLOOD PRESSURE REGULATION; BONE DISEASE; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COGNITIVE DEFECT; DISEASE CLASSIFICATION; DISEASE SEVERITY; ELDERLY CARE; GERIATRIC ASSESSMENT; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY FAILURE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT REFERRAL; PRACTICE GUIDELINE; PROGNOSIS; PROTEINURIA; QUALITY OF LIFE; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR;

CHRONIC KIDNEY DISEASE; DIALYSIS; ELDERLY; GERIATRIC; RENAL FUNCTION;

AGED; AGING; BIAS (EPIDEMIOLOGY); DISEASE MANAGEMENT; DISEASE PROGRESSION; GERIATRIC ASSESSMENT; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MONITORING, PHYSIOLOGIC; ORGAN DYSFUNCTION SCORES; PATIENT ACUITY; PATIENT OUTCOME ASSESSMENT; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 84880121650     PISSN: 07490690     EISSN: 18798853     Source Type: Journal    
DOI: 10.1016/j.cger.2013.05.003     Document Type: Review

References (57)

1. Centers for Disease Control and Prevention. Public health and aging: trends in aging-United States and worldwide. JAMA 2003, 289(11):1371-1373.
2. Stevens L.A., Coresh J., Levey A.S. CKD in the elderly-old questions and new challenges: World Kidney Day 2008. Am J Kidney Dis 2008, 51(3):353-357.
3. Collins A.J., Foley R.N., Chavers B., et al. United States renal data system 2011 Annual data report: atlas of chronic kidney disease & end-stage renal disease in the United States. Am J Kidney Dis 2012, 59(1 Suppl 1):A7. e1-420.
4. Collins A.J., Foley R.N., Herzog C., et al. Excerpts from the US renal data system 2009 Annual data report. Am J Kidney Dis 2010, 55(1 Suppl 1):S1-S420. A6-7.
5. Coresh J., Astor B.C., Greene T., et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41(1):1-12.
6. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298(17):2038-2047.
7. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002, 39(2 Suppl 1):S1-S266.
8. Levey A.S., Bosch J.P., Lewis J.B., et al. Amore accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130(6):461-470.
9. Brook M.O., Bottomley M.J., Mevada C., et al. Repeat testing is essential when estimating chronic kidney disease prevalence and associated cardiovascular risk. QJM 2012, 105(3):247-255.
10. Levey A.S., de Jong P.E., Coresh J., et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int 2011, 80(1):17-28.
11. Rule A.D., Larson T.S., Bergstrath E.J., et al. Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease. Ann Intern Med 2004, 141(12):929-937.
12. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013, 3:1-150.
13. Earley A., Miskulin D., Lamb E.J., et al. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Intern Med 2012, 156(11):785-795. W-270, W-271, W-272, W-273, W-274, W-275, W-276, W-277, W-278.
14. Schold J.D., Navaneethan J.D., Jolly S.E., et al. Implications of the CKD-EPI GFR estimation equation in clinical practice. Clin J Am Soc Nephrol 2011, 6(3):497-504.
15. Schaeffner E.S., Ebert N., Delanaye P., et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Intern Med 2012, 157(7):471-481.
16. Randers E., Erlandsen E.J. Serum cystatin C as an endogenous marker of the renal function-a review. Clin Chem Lab Med 1999, 37(4):389-395.
17. Shlipak M.G., Sarnak M.J., Katz R., et al. Cystatin C and the risk of death and cardiovascular events among elderly persons. NEngl J Med 2005, 352(20):2049-2060.
18. Inker L.A., Schmid C.H., Tighiouart H., et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. NEngl J Med 2012, 367(1):20-29.
19. Peralta C.A., Katz R., Sarnak M.J., et al. Cystatin C identifies chronic kidney disease patients at higher risk for complications. JAm Soc Nephrol 2011, 22(1):147-155.
20. Rowe J.W., Adres R., Tobin J.D., et al. The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. JGerontol 1976, 31(2):155-163.
21. Lindeman R.D., Tobin J., Shock N.W. Longitudinal studies on the rate of decline in renal function with age. JAm Geriatr Soc 1985, 33(4):278-285.
22. Soares C.M., Diniz J.S., Lima E.M., et al. Predictive factors of progression to chronic kidney disease stage 5 in a predialysis interdisciplinary programme. Nephrol Dial Transplant 2009, 24(3):848-855.
23. Young J.H., Klag M.J., Muntner P., et al. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). JAm Soc Nephrol 2002, 13(11):2776-2782.
24. Chobanian A.V., Bakris G.L., Black H.R., et al. The Seventh report of the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2572.
25. Klahr S., Levey A.S., Beck G.J., et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. NEngl J Med 1994, 330(13):877-884.
26. Wright J.T., Bakris G., Greene T., et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 2002, 288(19):2421-2431.
27. Kramer H.J., Nguyen Q.D., Curhan G., et al. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003, 289(24):3273-3277.
28. O'Hare A.M., Kaufman J.S., Covinsky K.E., et al. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults?. Ann Intern Med 2009, 150(10):717-724.
29. Weiss J.W., Thorp M.L., O'Hare A.M. Renin-angiotensin system blockade in older adults with chronic kidney disease: a review of the literature. Curr Opin Nephrol Hypertens 2010, 19(5):413-419.
30. Winkelmayer W.C., Zhang Z., Shahinfar S., et al. Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes. Diabetes Care 2006, 29(10):2210-2217.
31. Johnson E.S., Weinstein J.R., Thorp M.L., et al. Predicting the risk of hyperkalemia in patients with chronic kidney disease starting lisinopril. Pharmacoepidemiol Drug Saf 2010, 19(3):266-272.
32. Weinberg J.M., Appel L.J., Bakris G., et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med 2009, 169(17):1587-1594.
33. Rahman M., Ford C.E., Cutler J.A., et al. Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol 2012, 7(6):989-1002.
34. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. NEngl J Med 2009, 360(2):129-139.
35. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. NEngl J Med 2008, 358(24):2545-2559.
36. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. NEngl J Med 2008, 358(24):2560-2572.
37. Moen M.F., Zhan M., Hsu V.D., et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol 2009, 4(6):1121-1127.
38. Nordin C. The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence. Diabetologia 2010, 53(8):1552-1561.
39. Zoungas S., Patel A., Chalmers J., et al. Severe hypoglycemia and risks of vascular events and death. NEngl J Med 2010, 363(15):1410-1418.
40. O'Hare A.M., Choi A.L., Bertenthal D., et al. Age affects outcomes in chronic kidney disease. JAm Soc Nephrol 2007, 18(10):2758-2765.
41. Fried L.F., Shlipak M.G., Crump C., et al. Renal insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. JAm Coll Cardiol 2003, 41(8):1364-1372.
42. Manjunath G., Tighiouart H., Coresh J., et al. Level of kidney function as a risk factor for cardiovascular outcomes in the elderly. Kidney Int 2003, 63(3):1121-1129.
43. Rifkin D.E., Katz R., Chonchol M., et al. Albuminuria, impaired kidney function and cardiovascular outcomes or mortality in the elderly. Nephrol Dial Transplant 2010, 25(5):1560-1567.
44. Baigent C., Landray M.J., Reith C., et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 2011, 377(9784):2181-2192.
45. Palmer S.C., Craig J.C., Navaneethan S.D., et al. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012, 157(4):263-275.
46. Upadhyay A., Earley A., Lamont J.L., et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012, 157(4):251-262.
47. Murray A.M. Cognitive impairment in the aging dialysis and chronic kidney disease populations: an occult burden. Adv Chronic Kidney Dis 2008, 15(2):123-132.
48. Weiner D.E., Bartolomei K., Scott T., et al. Albuminuria, cognitive functioning, and white matter hyperintensities in homebound elders. Am J Kidney Dis 2009, 53(3):438-447.
49. Kurella Tamura M., Covinsky K.E., Chertow G.M., et al. Functional status of elderly adults before and after initiation of dialysis. N Engl J Med 2009, 361(16):1539-1547.
50. Fried L.F., Lee J.S., Shlipak M., et al. Chronic kidney disease and functional limitation in older people: health, aging and body composition study. JAm Geriatr Soc 2006, 54(5):750-756.
51. Shlipak M.G., Stehman-Breen C., Fried L.F., et al. The presence of frailty in elderly persons with chronic renal insufficiency. Am J Kidney Dis 2004, 43(5):861-867.
52. Johansen K.L., Chertow G.M., Kutner N.G., et al. Low level of self-reported physical activity in ambulatory patients new to dialysis. Kidney Int 2010, 78(11):1164-1170.
53. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009, (113):S1-S130.
54. Seiler S., Heine G.H., Fliser D. Clinical relevance of FGF-23 in chronic kidney disease. Kidney Int Suppl 2009, (114):S34-S42.
55. Fried L.F., Shlipak M.G., Stehman-Breen C., et al. Kidney function predicts the rate of bone loss in older individuals: the Cardiovascular Health Study. JGerontol A Biol Sci Med Sci 2006, 61(7):743-748.
56. Hsu C.Y., Cummings S.R., McCulloch C.E., et al. Bone mineral density is not diminished by mild to moderate chronic renal insufficiency. Kidney Int 2002, 61(5):1814-1820.
57. Yenchek R.H., Ix J.H., Shlipak M.G., et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 2012, 7(7):1130-1136.